Sanofi stock dips on Trump vaccine order but growth outlook remains strong with raised 2026 sales guidance.

Sanofi's stock faced pressure after President Trump signed Executive Order 14420, which included recommendations on childhood vaccines. Despite this, Sanofi trades at a significant discount with a forward non-GAAP P/E ratio of 9.2x, well below the sector median. The company also raised its 2026 sales growth guidance to around 10% at constant exchange rates, reflecting confidence in its immune-mediated inflammatory diseases and vaccines franchises. Recent Q2 earnings showed stronger-than-expected sales growth for key products, supporting a positive risk/reward profile for investors.